Dr. Keyan Salari, a urologic oncologist at Massachusetts General Hospital and instructor in surgery, Harvard Medical School discusses his Abstract presentation from the American Urological Association (AUA2020) Annual Meeting titled “5-alpha reductase inhibitors and risk of overall and fatal bladder cancer”.
Keyan Salari, MD, PhD is a urologic oncologist at the Massachusetts General Hospital Department of Urology and Harvard Medical School. He is a urologic surgeon specialized in the treatment of genitourinary cancers using open, laparoscopic, and robotic surgery techniques. His research focuses on applying cancer genomics and computational biology methods to advance precision cancer medicine for genitourinary malignancies.
Dr. Salari is a faculty member of the Department of Urology and a Urologic Oncologist at Massachusetts General Hospital. He graduated with honors from the University of California at Berkeley with a B.A. in molecular and cellular biology, where he was awarded the Spencer W. Brown Award for the best undergraduate thesis in genetics and was a Howard Hughes Medical Institute Biology Fellow. He earned his MD and Ph.D. in Genetics from Stanford University School of Medicine in the NIH Medical Scientist Training Program. He trained in General Surgery and Urology at the Massachusetts General Hospital and subsequently completed a fellowship Urologic Oncology at Memorial Sloan Kettering Cancer Center.
Dr. Salari’s clinical practice focuses on the surgical treatment of urologic cancers with a particular emphasis on prostate cancer and testicular cancer. His research interests focus on leveraging a variety of genomic technologies and computational biology methods to gain insight into the pathobiology of prostate cancer, with the goal of improving early detection of clinically significant prostate cancer and distinguishing indolent from aggressive disease to guide treatment decisions.